Given the known correlations between levels of VEGF expression and tumor dysplasia (25) and lowered rates of survival (24), testing patients’ tumors for VEGF expression prior to treatment may be a plausible method to estimate possible effectiveness of anti-angiogenic treatment. The gene discussed is VEGFA; the disease is neoplasm.